Type of surgical approach-open or robot assisted-appears to have no effect on specific clinical outcomes in patients undergoing radical prostatectomy for high-risk prostate cancer, nor does the procedure influence the pathway subsequent therapy might follow, according to a recent study.
More than 85% of patients undergoing robot-assisted laparoscopic prostatectomy may not require opioid analgesia either immediately post-op, in hospital, or upon release, according to a recent study.
A recently published study found that a small percentage of men who seek infertility treatment are potentially hurting their ability to have children by taking testosterone supplements.
A lawsuit was filed against both the urologist and the radiologist involved in the treatment of the kidney stone, claiming that he was not informed of the abnormality on the left kidney noted on the CT scan and the recommendation for follow-up.
Although testosterone use has increased significantly among older men in the past decade, many patients appear to have normal testosterone levels and do not meet the clinical guidelines for treatment, according to new research.
Both the death rate and incidence rate for prostate cancer continues to decline, according to the latest round of statistics from leading U.S. cancer groups.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington in Seattle have developed a personalized tool that they say can predict the likelihood of prostate cancer overdiagnosis.
PSA screening has likely played an important role in the 40%-plus drop in prostate cancer mortality since the late 1980s, although the mortality rate for metastatic disease has remained the same, say study authors from the University of California, Davis.
The controversial oil and natural gas drilling technique called hydraulic fracturing, or fracking, uses many chemicals that can disrupt the body’s hormones, according to new research.
Signs of inflammation in a man’s prostate biopsy may indicate that he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy, according to the authors of a recently published study.
Insurance coverage has expanded for an epigenetic test for prostate cancer and percutaneous tibial nerve stimulation (PTNS) for the treatment of overactive bladder (OAB).
The top 10 Urology Times articles of 2013 encompass topics including prostate biopsy, the urology work force, and PSA screening.
The latest products and services from Lambert Academic Publishing, the AUA, United Guardian, and SpryPublishing.
Researchers say they have linked high testosterone levels in men to a poor immune response to an influenza vaccine.
With a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.
Out-of-pocket costs for couples being treated for infertility range from a low of $912 for medication only to $19,234 for in vitro fertilization, according to researchers who say their data will help couples plan for the expenses they may incur.
Risk classification changed in more than half of prostate cancers following assessment of cell cycle progression in tumors, according to a study reported at the Society of Urologic Oncology meeting in Bethesda, MD.
In this article, we briefly review the evaluation of patients with PPI and discuss the benefits and drawbacks of conservative, pharmacologic, injection, and surgical treatments.
The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop there, according to recent study.
The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).
The AUA recently joined with the American Association of Clinical Urologists and the Large Urology Group Practice Association in applauding the Physician’s Caucus of the United States Senate for their “commitment to preserving patient access to independent, integrated medical services.”
Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”
British scientists have discovered that the presence of a specific protein can distinguish between indolent and aggressive prostate cancer.
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.
Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.
